Altimmune Could Find A Partner For Its Phase 3 Exercise

Company Analysis - Altimmune's incretin drug, pemvidutide, shows promising prospects [1] - The company is awaiting the outcome of its end-of-phase 2 (EOP2) meeting with the U.S. FDA [1] Industry Focus - The biotech industry is heavily influenced by trial results and NDA/BLA approvals [2] - Companies in industries regulated by the FDA are a key focus area [2]